The pharmaceutical company AstraZeneca announced that it has the capacity to manufacture one billion doses of the vaccine against the new Coronavirus, which was recently developed by Oxford University, and that the company plans to start supplying it next September.
The Anglo-Swedish company stated that it had received more than $ 1 billion from the American Advanced Biomedical Research and Development Authority, to develop, produce and deliver the vaccine, beginning in the fall, according to the Sky News website.
The drug giant said it had already received a request from the US Vaccine Authority to produce about 400 million doses of the vaccine that Oxford University developed to combat the Coronavirus, the cause of Covid-19 disease.
The company added in a statement that it “has now guaranteed the ability to manufacture one billion doses, and aims to secure more agreements to expand capacity further in the coming months to ensure that the vaccine is available globally.”
Pascal Sariot, CEO of AstraZeneca, said that the investment will speed up the development and production of the vaccine. It has already been included in the British government’s investment.
“We need to defeat the virus together. Otherwise, our personal, economic and social suffering will continue for a long time,” he added, expressing his thanks to the American and British governments for their great support to accelerate the development and production of the vaccine.
He said: «We are very proud to cooperate with the University of Oxford to turn their pioneering work into a drug that can be produced on a global scale .. We will do our best to make this vaccine widely available.
The British government says that 30 million doses of the new “Oxford vaccine” could be available across the UK in September if proven effective.
The vaccine experiments, officially known as “Shaduk One One Coved 19”, began on April 24, to see if it could effectively protect healthy people from the Coronavirus.
A few days ago, British Business Secretary Alok Sharma confirmed that the first clinical trials were “going well” with all the volunteers who received a dose of the vaccine earlier this month.